News

Simulations Plus, a leading provider of model-informed and AI-enabled drug development software and services, has agreed to be acquired by healthcare-focused investment firm Altaris in…
Read More...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. Food and Drug Administration (FDA) have announced a new liaison programme aimed at strengthening…
Read More...

SpliSense has secured a funding commitment of up to $13 million from the Cystic Fibrosis Foundation to support the continued clinical development of its lead investigational therapy,…
Read More...

AviadoBio has expanded its partnership with King’s College London, securing exclusive rights to apply the vMiX™ RNA interference (RNAi) gene-silencing platform across all human…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in Jacksonville, Florida, to expand its Vision business operations and strengthen domestic manufacturing,…
Read More...

Alkermes plc has received significant regulatory recognition for its investigational sleep disorder therapy alixorexton, with health authorities in both the United States and Europe…
Read More...

Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking a significant expansion of its rare diseases business and adding a recently approved hereditary…
Read More...

Johnson & Johnson has reported positive results from the Phase 2/3 ENERGY study evaluating IMAAVY® (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a…
Read More...

GSK has received a significant regulatory boost for its investigational efforts in rare diseases after both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency…
Read More...

Roche has moved a step closer to expanding the use of its immunotherapy Tecentriq® (atezolizumab) in early-stage colon cancer after the U.S. Food and Drug Administration (FDA) accepted…
Read More...

Akeso has secured regulatory approval in China for gumokimab (AK111), its internally developed anti-IL-17 monoclonal antibody, for the treatment of adults with moderate-to-severe plaque…
Read More...

Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company focused on developing therapies against historically difficult-to-target disease-driving proteins, has successfully…
Read More...

XtalPi has entered into a strategic collaboration with a leading international biopharmaceutical company to develop a next-generation small-molecule therapy targeting a complex G…
Read More...

The United Kingdom has become the first country in Europe to approve Wegovy® pill (semaglutide tablets) for weight management, providing adults living with obesity or overweight a new…
Read More...

DePuy Synthes, a leader in orthopedic technologies and part of Johnson & Johnson MedTech, has announced the U.S. commercial launch of VELYS™ Hip Navigation with AI Assistance, a…
Read More...

Eli Lilly and Company has launched a new national awareness campaign featuring basketball legend Shaquille O’Neal to spotlight moderate-to-severe obstructive sleep apnea (OSA), a common…
Read More...

Bayer has reached an important regulatory milestone for its investigational stroke prevention therapy as the European Medicines Agency (EMA) has validated and begun reviewing the…
Read More...

Beren Therapeutics P.B.C. has raised $300 million in combined financing to support the development and potential commercialization of its investigational therapy adrabetadex, a…
Read More...

GSK has agreed to acquire clinical-stage biotechnology company Nuvalent for approximately $10.6 billion, strengthening its oncology portfolio with a trio of targeted lung cancer…
Read More...

Aditxt, Inc. has announced a definitive business combination agreement that will enable its wholly owned subsidiary, Ignite Proteomics, to become an independent publicly traded company…
Read More...